Wegovy 2.4 mg: the maintenance dose explained

You've been titrating for months and the 2.4 mg dose is finally in reach

If you're reading this, there's a reasonable chance you're somewhere in the middle of Wegovy's titration schedule, counting the weeks until you reach 2.4 mg. That feeling (a mix of anticipation and impatience) is something our prescribers hear about regularly. It helps to know exactly what you're building towards.

The full Wegovy dosing ladder runs from 0.25 mg up through 0.5 mg, 1.0 mg and 1.7 mg before arriving at 2.4 mg, with roughly four weeks spent at each level. The earlier steps are not therapeutic holding patterns, they are doing real work settling your system so that, by the time you reach 2.4 mg, the side-effect burden is as low as possible. Skipping rungs increases the chance of significant nausea and, sometimes, early dropout.

At 2.4 mg, semaglutide's GLP-1 receptor activity is fully established. It slows gastric emptying, signals satiety to the brain and reduces the baseline appetite that makes sustained calorie reduction so difficult without pharmacological support. For the majority of people on the standard titration, this is where the most meaningful weight loss tends to occur. The NHS medicines page for semaglutide has patient-level detail on how it works if you'd like the fuller picture.

One practical note: moving from 1.7 mg to the 2.4 mg Wegovy dose means moving to a different pen device, so check the packaging carefully and read the instructions before your first injection at the new strength.

What the STEP 1 trial actually showed at 2.4 mg, and the honest framing around it

The headline figure most people have seen is approximately 15% average body-weight reduction over 68 weeks in the STEP 1 trial. That number is accurate, but context matters.

STEP 1 enrolled adults with obesity or overweight plus at least one weight-related condition, all without type 2 diabetes, and all receiving structured lifestyle support alongside the medication. Average weight loss across the group on 2.4 mg semaglutide was around 14.9%, often quoted as roughly 15%. Participants on placebo lost around 2.4%, making the drug's contribution substantial. The trial was published in the New England Journal of Medicine and underpins the MHRA's licensed indication for Wegovy in the UK.

What the average doesn't capture is the range. Some participants lost considerably more; others lost less. Biology, diet quality, activity level and adherence all influence individual outcomes. That's not a disclaimer designed to soften expectations, it's the honest clinical picture, and it's why a prescriber reviews your progress rather than a fixed algorithm.

For context on whether weight loss tends to be greater at higher doses, the page on weight loss at higher Wegovy doses covers what the evidence shows now that 7.2 mg is available.

If you're comparing Wegovy at 2.4 mg to other treatment options, the weight-loss treatments overview at nume sets out the medicines we prescribe and what the clinical evidence looks like across them.

Side effects at 2.4 mg: what typically changes when you step up

For most people, the jump from 1.7 mg to 2.4 mg is when gastrointestinal effects are most noticeable, nausea, constipation, loose stools and occasionally vomiting are the most commonly reported. In the STEP 1 trial, gastrointestinal events were the most frequent reason for discontinuation, though serious events were uncommon.

The good news is that these effects are almost always transient, peaking in the first week or two after a dose change and then settling. Eating smaller meals, avoiding high-fat foods while your body adjusts, staying well hydrated and injecting on the same day each week all help. Your Patient Information Leaflet contains the complete list of potential effects at every strength.

One area that warrants specific attention: the MHRA highlighted acute pancreatitis as a known, though infrequent, side effect of GLP-1 medicines in a Drug Safety Update. If you develop severe stomach pain that moves through to your back (with or without vomiting) seek medical help promptly rather than waiting to see if it passes.

For a fuller look at how side effects tend to shift as the dose goes up, this page on Wegovy side effects and dosage goes into more detail. Suspected side effects can be reported to the MHRA via the Yellow Card scheme.

The 2.4 mg dose within the UK's licensed framework

NICE's appraisal of semaglutide for weight management recommends it for adults with a BMI of 35 or above and at least one weight-related comorbidity, within a specialist weight management service, for a maximum of two years. Ethnic-background thresholds are typically set 2.5 kg/m² lower under UK guidance. The NHS route carries waiting lists that are, in many areas, substantial.

Private prescription allows access without those waiting times, subject to a clinical assessment confirming eligibility. If you're exploring that route, it's worth reading about what Wegovy 2.4 mg means in the UK specifically, the licensed criteria, what the prescription process looks like and how private care differs from NHS pathways.

On cost: private Wegovy treatment is priced per month and varies between providers by dose and what's included. Any legitimate price should incorporate the clinical assessment, prescription and aftercare, not just the pen itself. If the cost breakdown by Wegovy strength is useful context, that page covers market pricing factually. The right question isn't which provider is cheapest; for a prescription medicine, the right question is which provider is clinically rigorous and genuinely accountable.

If you have questions about your eligibility or you're thinking about starting treatment, speaking to our prescribers is the sensible first step. Consultations at nume are free, reviewed the same day by a named prescriber, and there's no obligation to proceed.